Impact Proteomics provides a proprietary antigen profiling and protein identification platform that analyzes patient samples to map disease-associated antigens without cloned intermediates. The company serves biotechnology and diagnostic partners by enabling target discovery, companion diagnostics development, and therapeutic selection for oncology and autoimmune diseases.
Subscribe to see Impact Proteomics, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Impact Proteomics, LLC is a biotechnology company headquartered in Pittsburgh, United States. It has raised at least $250,000 across the 2 funding rounds on record. Its most recent funding round raised $50,000 in August 2024. Xcout tracks 1 named person at Impact Proteomics, LLC, including Frederick Strathmann (Member of the Board of Directors).
As of 16 November 2026. Source: Xcout Intel.
At least $250,000 raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $50,000 | — | |
| SEC Form D filing | $200,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Impact Proteomics, LLC's closest competitors — see the full list of competitors and alternatives →
Novigenix is an immuno-transcriptomics and TechBio company that provides precision oncology solutions for biopharmaceutical companies and researchers. It offers LITOseek, an AI-powered liquid biopsy platform that analyzes gene activity in immune cells to support biomarker discovery, therapy development, and patient response monitoring.
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
OncoHost is an Israeli precision-oncology biotechnology company that develops blood-based proteomic tests and computational analytics to characterize cancer patients and predict responses to immunotherapy. Its products are intended to help oncologists personalize treatment decisions and identify mechanisms of resistance, serving cancer patients, clinicians, pharmaceutical companies, and researchers.
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
Enara Bio is a biotechnology company headquartered in Oxford, Oxfordshire, backed by prominent life science investors. The company focuses on advancing cancer immunotherapy by targeting novel Dark Antigen assets.
Cofactor Genomics develops RNA-Seq technology and predictive diagnostics to help match cancer patients with appropriate immunotherapy treatments. The company offers tools such as the OncoPrism assay and collaborates with healthcare systems and clinical researchers to evaluate multidimensional biomarkers for various solid tumor cancers.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Impact Proteomics, LLC? Suggest a correction · Work at Impact Proteomics, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.